dibekacin and Cholecystitis

Cefoxitin (CFX) was administrated to a total of 12 hospitalized patients with digestive diseases, in combination with aminoglycosides. The following results were obtained: Clinical effects of CFX on 12 cases were "excellent" in 4 cases, "good" in 5, "fair" in 1 and "unknown" in 2, with the efficacy rate of 75%. All 4 cases who developed septicemia with underlying severe diseases showed "excellent" effect to CFX. Clinical results of 8 cases with hepatic biliary tract infections were "good" in 5, "fair" in 1 and "unknown" in 2, with the efficacy rate in 62.5%. As for side effects, an allergic reaction was observed in 1 case, and it is suggested renal function should be monitored carefully in a case of combination use with aminoglycosides.

Topics: Aged; Bacterial Infections; Biliary Tract Diseases; Cefoxitin; Cholecystitis; Dibekacin; Digestive System Diseases; Drug Therapy, Combination; Female; Gallstones; Gentamicins; Humans; Liver Abscess; Male; Middle Aged; Sepsis

An antibiotic drug of aminoglycoside group, dibekacin (DKB) for parental use was used in 48 patients hospitalized due to acute or subacute infection of abdominal organs: 36 appendicitis, 9 cholecystitis and 3 others. DKB in a dose of 100 mg was given intramuscularly in 38 cases, and in 10 cases was given intravenously by single or drip infusion before the operation. The materials of A-bile, B-bile, wall of gallbladder, the appendix wall, ascites with pus and serum were taken during the operation. DKB concentration was measured by bioassay method with Bacillus Subtilis ATCC 6633 strain. With a few marked exceptions, DKB concentration in B-bile were higher than those in A-bile. DKB concentrations in gallbladder wall and appendix wall were directly proportional to the degree of pathological changes of inflammation. DKB concentrations in infected tissues after intravenous drip infusion, they were higher relatively than those after intramuscular administration. DKB concentrations in serum after intravenous drip infusion reached to peak immediately the end of infusion, and in the infected tissue they reached to peak at the same time and stayed for a relatively long time, then they were declined slowly. For the therapeutic purpose, DKB was given to the 6 patients with acute peritonitis of the above cases. DKB in a dose of 100 mg were administered by intravenous drip infusion for 2 hours, twice in a day for 3 - 10 days. Clinical response was excellent in 2 cases, good in 3 cases, fair in 1 case and poor in none. No adverse effect was observed. Therefore, it was supposed that DKB could be used safely by intravenous drip infusion.

Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Bacterial Agents; Appendicitis; Child; Cholecystitis; Dibekacin; Female; Humans; Infusions, Parenteral; Injections, Intramuscular; Kanamycin; Male; Middle Aged; Peritonitis; Tissue Distribution